Activation of the Poly(ADP-Ribose) Polymerase Pathway in Human Heart Failure by Molnár, Andrea et al.
INTRODUCTION
Acute and chronic heart failure are
major causes of hospitalization, morbidity,
and mortality worldwide. The mecha-
nisms leading to cardiac pump failure
may have various origins and include
acute and chronic ischemic heart diseases
that can develop on the basis of an altered
coronary artery circulation or infarction,
cardiomyopathies, myocarditis, a pressure
overload and defects in the genes encod-
ing the contractile apparatus, the intercel-
lular matrix, the cytoskeleton, and the mi-
tochondrial proteins, among many others.
These defects result in a mismatch be-
tween the load applied to the heart and
the energy needed for contraction, leading
to mechanoenergic uncoupling (1-3).
The pathomechanism of heart failure is
complex and can include the activation of
numerous secondary pathways (involving
neurohormones, neuropeptides, cytokines,
inducible nitric oxide synthase [iNOS],
and oxidative/nitrosative stress), leading
to abnormalities in various signaling
processes and cardiac receptors, calcium
homeostasis, contractile protein alter-
ations, and endothelial dysfunction. The
resultant structural alterations give rise to
cardiac and vascular remodeling with hy-
pertrophy, fibrosis, cardiac dilation, and
myocardial necrosis. The adverse remodel-
ing and increased peripheral resistance
further aggravate heart failure (1,2).
Recent work, mainly on various ani-
mal models of heart failure, has pro-
vided evidence of the pathogenetic role
of oxidative and nitrosative stress and
downstream mechanisms, including the
activation of matrix metalloproteinases
(MMPs) and poly(ADP-ribose) poly-
merase (PARP), in various forms of
heart failure (1-6). These studies have
also suggested that these pathways may
allow potential novel therapeutic possi-
bilities. To validate these pathways and
targets, it is essential to assess the acti-
vation of these pathways in human
samples. In the present study, using
clinical tissue material, we have com-
pared healthy donor myocardial sam-
ples and myocardial samples from fail-
ing hearts, to obtain evidence for
oxidative and nitrosative stress and
PARP activation.
MATERIALS AND METHODS
Left Ventricular Tissue Samples
Healthy human hearts were obtained
from 5 general organ donor patients
whose hearts were explanted to obtain
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late PARP activation with various indices of apoptosis and oxidative and nitrosative stress in healthy (donor) and failing (NYHA class
III-IV) human heart tissue samples. Higher levels of oxidized protein end-products were found in failing hearts compared with donor
heart samples. On the other hand, no differences in tyrosine nitration (a marker of peroxynitrite generation) were detected. Acti-
vation of PARP was demonstrated in the failing hearts by an increased abundance of poly-ADP ribosylated proteins. Immunohis-
tochemical analysis revealed that PARP activation was localized to the nucleus of the cardiomyocytes from the failing hearts. The
expression of full-length PARP-1 was not significantly different in donor and failing hearts. The expression of caspase-9, in contrast,
was significantly higher in the failing than in the donor hearts. Immunohistochemical analysis was used to detect the activation of
mitochondrial apoptotic pathways. We found no significant translocation of apoptosis-inducing factor (AIF) into the nucleus. Over-
all, the current data provide evidence of oxidative stress and PARP activation in human heart failure. Interventional studies with
antioxidants or PARP inhibitors are required to define the specific roles of these factors in the pathogenesis of human heart failure.
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pulmonary and aortic valves for trans-
plant surgery (donor hearts). The donors
did not show any sign of cardiac abnor-
malities and did not receive any medica-
tion except plasma volume expanders,
dobutamine, and furosemide. The causes
of death included cerebral contusion due
to accidents and cerebral hemorrhage or
subarachnoid hemorrhage due to stroke.
Failing hearts were obtained from 8 ex-
planted end-stage failing hearts (NYHA
class III-IV). Both the failing and the
donor hearts were kept in cardioplegic
solution (110 mM NaCl, 16 mM KCl, 1.6
mM MgCl2, 1.2 mM CaCl2, and 5 mM
NaHCO3) until their arrival to the labora-
tory. A detailed summary of the pretrans-
plant data and drug therapy is shown on
Table 1. The experiments complied with
the Helsinki Declaration of the World
Medical Association and were approved
by the Albert Szent-Györgyi Medical
University Ethical Review Board (no. 51-
57/1997.OEj). Left ventricular wall sam-
ples were obtained from the base. All
biopsies were stored in cardioplegic solu-
tion and kept at 4 °C for approximatelly
6 to 8 h before being frozen in liquid ni-
trogen. Subsequently, the tissue samples
were stored at –80 °C.
Immunohistochemical Analysis of
Poly(ADP-Ribose) (PAR) and
Apoptosis Inducing Factor (AIF)
Human ventricular tissue samples
were frozen in Tissue-Tek OCT com-
pound (Electron Microscopy Sciences,
Hatfield, PA, USA). Cryostat sections of
5 μm were placed on adhesive slides
and fixed in acetone for 10 min. En-
dogenous peroxidase activity was sup-
pressed by treating the slides with
0.3% H2O2 in methanol for 30 min. Sec-
tions were washed 3 times in 0.01 M
PBS (pH 7.4) and blocked with 1.5%
normal goat serum (Vector Laboratories,
Burlingame, CA, USA) in PBS contain-
ing 0.2% Triton X-100 (blocking serum)
for 60 min. Primary antibody against
PAR polymers (anti-PAR; Calbiochem,
San Diego, CA, USA) and AIF (anti-AIF;
Chemicon International, Temecula, CA,
USA) were applied at a dilution of 1:100
in blocking serum and sections were in-
cubated overnight at 4 °C. After wash-
ing in PBS containing 0.2% Triton X-100
(wash buffer), sections were incubated
with biotinylated anti-rabbit antibodies
(1:200 in blocking serum; Vector Labora-
tories, Burlingame, CA, USA) for 30
min. Sections were washed in wash
buffer and incubated with ABC peroxi-
dase reagent (Vectastain Elite ABC kit;
Vector Laboratories) for 30 min. After
washing in wash buffer, sections were
rinsed in PBS, and peroxidase activities
were revealed with 3,3′-diaminobenzi-
dine tetrahydrochloride (DAB) and
H2O2 (DAB substrate kit; Vector Labora-
tories). Slides were washed and counter-
stained with Gill’s hematoxylin (Accus-
tain; Sigma Diagnostics, St. Louis, MO,
USA), dehydrated in an ascending alco-
hol series, cleared in xylene, and cover-
slipped with Permount (Fischer Chemi-
cals, Fairlawn, NJ, USA). As a negative
control, sections were simultaneously
stained with omission of the primary
antibodies (7). Figures show representa-
tive staining patterns from 4 to 6 sepa-
rate sections.
To quantify the immunohistochemical
data in cases of PAR staining, the posi-
tive and negative nuclei were counted in
the view field of the microscope. At least
3 different failing or donor samples were
analyzed. Data are shown as percentages
of positive nuclei in the case of PAR
staining.
Detection of Poly-ADP-Ribosylation
Human left ventricular tissue samples
weighting 0.21 to 0.37 g were placed
into prechilled small glass tissue ho-
mogenizers with about 0.5 mL isolating
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Figure 1. Detection of oxidized proteins. About 0.3 g (wet weight) of ventricular tissues was
homogenized in RIPA buffer; 3 μg protein was used for the experiments. Samples are indi-
cated above the lanes (F, failing; D, donor). The optical densities of oxidized protein–derived
bands (the evaluated band is indicated) were corrected to the loading, and mean values
and SEM are shown in the bar graph (donor, n = 5; failing, n = 8; P = 0.02).
solution (5 mM Na2ATP, 6 mM MgCl2,
15 mM Na2-creatine phosphate, 20 mM
imidazole, 91 mM KCl, 2 mM EGTA,
and 1% vol/vol protease inhibitor cock-
tail) (Sigma-Aldrich). The tissue sam-
ples were mechanically disrupted at me-
dium speed. The homogenates were
centrifuged for 20 min at 14,000g. The
pellets were discarded and the protein
concentrations of the supernatants were
determined according to the BCA method
(Sigma-Aldrich). Subsequently, aliquots
of 20 μg supernatant boiled in SDS load-
ing buffer (total volume 40 ul) were
used for Western immunoblot analysis.
Electrophoresis was performed on 10%
SDS-polyacrylamide gels, followed by
transfer to nitrocellulose membranes
(Bio-Rad Laboratories, Hercules, CA,
USA). For the detection of poly-ADP-ri-
bosylated proteins, membranes were
probed with an anti-PAR antibody (de-
veloped in rabbit, dilution 1:10,000; Cal-
biochem) followed by an anti-rabbit sec-
ondary antibody (dilution 1:10,000;
Sigma-Aldrich), and the bands were de-
tected by enhanced chemiluminescence
(PerkinElmer Life Sciences, Boston, MA,
USA).
Oxidized Protein, PARP-1, Caspase-9,
and Nitrotyrosine Detection
Human left ventricular tissue samples
were homogenized as mentioned above,
except that RIPA buffer (1% Igepal CA-
630 [Sigma-Aldrich], 0.5% sodium deoxy-
cholate [Reanal Finechemical, Budapest,
Hungary], 0.1% sodium dodecylsulfate,
2% vol/vol protease inhibitor cocktail
[Sigma-Aldrich], 0.5 mM PMSF [Fluka,
Buchs, Switzerland], and 1 mM benzami-
dine hydrochloride hydrate [Sigma-
Aldrich]) was used instead of isolation
buffer. The homogenates were centrifuged
for 20 min at 14,000g and supernatants
were used for further determinations.
To detect the carbonyl groups caused
by oxidation of protein side-chains, an
OxyBlot oxidized protein detection kit
(Oncor, Gaithersburg, MD, USA) was
used according to the manufacturer’s in-
structions(8). The protein contents of the
samples were determined by the BCA
method. Each sample (3 mg) was diluted
to 5 mL with water, and an equal volume
of 12% SDS was added. DNP (10 mL)
was added, and the reaction was allowed
to proceed at room temperature for 15
min. Neutralization solution (7.5 mL of
0.74 M 2-mercaptoethanol) was added to
stop the reaction. The supernatant
treated in the absence of DNP served as
a negative control. The derived samples
and standards were loaded onto 10%
SDS-polyacrylamide minigels, and the
proteins were transferred to nitrocellu-
lose membranes. The membranes were
then blocked with 1% BSA in PBS-T
(0.1% Tween-20 containing PBS [150 mM
NaCl, 8 mM Na2HPO4, 2 mM NaH2PO4,
pH 7.4] [Sigma-Aldrich]) for 1 h at room
temperature under continuous agitation
on an orbital shaker. The blocked mem-
branes were incubated with rabbit anti-
DNP 1:150 in 1% BSA/PBS-T for 1 h,
washed, and incubated with goat anti-
rabbit IgG-HRP 1:300 in 1% BSA in
PBS-T for 1 h. The positive bands were
detected with an ECL chemiluminescent
reagent.
For the detection of PARP-1, caspase-9,
and nitrotyrosine, 15 to 30 mg/lane pro-
tein (supernatants of the homogenates)
was loaded onto 10% SDS-polyacrylamide
minigel (for PARP-1 and caspase-9) or
5% to 20% SDS-polyacrylamide gradient
gel (for nitrotyrosine). After separation,
proteins were transferred to nitrocellu-
lose membrane. The membranes were
blocked with 1% BSA in PBS-T for 1 h on
an orbital shaker and then probed with
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Figure 2. Detection of protein nitration. Human ventricular tissue homogenates (F, fail-
ing; D, donor) were loaded (30 μg of protein in each lane) onto 5% to 20% gradient
SDS-polyacrylamide gels and probed with a nitrotyrosine-specific antibody (1:10,000;
Calbiochem). It should be noted that the major band (indicated) is recognized by the
secondary antibody alone and is therefore not specific to nitrotyrosine. A positive con-
trol for nitrotyrosine staining (sample F7 treated with 500 μM peroxynitrite for 5 min) is
shown on the right.
rabbit anti-PARP-1 antibody (Calbiochem)
at a dilution of 1:10,000, rabbit anti-
caspase-9 antibody (Cell Signaling Tech-
nology, Beverly, MA, USA) at a dilution
of 1:1,000, or rabbit anti-nitrotyrosine
antibody (Calbiochem) at a dilution of
1:10,000 in 1% BSA in PBS-T for 1 h.
The blots were then incubated with a
HRP-conjugated anti-rabbit secondary
antibody (Sigma-Aldrich) or with a
biotinylated secondary antibody (for
nitrotyrosine staining, Vectastain ABC
kit; Vector Laboratories), and the
immunoreactive proteins were visual-
ized using an ECL detection reagent
(PerkinElmer Life Sciences) and X-ray
autoradiographic film (Agfa-Gevaert,
Belgium).
For nitrotyrosine detection, one of the
failing samples (F7) was treated with 10 to
500 μM peroxynitrite for 5 min at room
temperature (5 mL of 10 mM peroxynitrite
[Calbiochem] in 150 mM KCl, pH 11, was
added to 95 mL of tissue homogenate) and
was used as positive control for nitrotyro-
sine staining (see Figure 2).
Densitometric Analysis of the Bands
X-ray films were scanned and evalu-
ated with ImageJ v 1.32 software
(www.nih.gov). The densities of the
bands of interest (shown in the figures)
were measured and corrected for the den-
sity of the actin band on the same mem-
branes visualized by Ponceau (Sigma-
Aldrich) staining (loading control). The
corrected optical densities from the same
or parallel membranes were calculated,
and the differences between the donor
and the failing samples were evaluated
with Student t test. The data presented in
the graphs are means ± SEM.
RESULTS
Overall, we set out to investigate some
of the pathological events occurring dur-
ing human heart failure that lead to
apoptosis of the ventricular myocytes,
and therefore, to progression of the dis-
ease. To determine the levels of oxidized
proteins in the donor and failing heart
samples, tissues were screened for car-
bonyl adducts (8). Compared with the
donor heart samples, strong immuno-
reactivity for oxidized protein end-
products was readily detected in the
failing hearts (Figure 1). As assessed by
semiquantitative densitometry, the level
of carbonyl adducts was increased ap-
proximately 3-fold (38.7 ± 12.1, n = 5, in
the donor hearts and 118.3 ± 22.3, n = 8,
in the failing hearts; P = 0.02).
The higher production of superoxide
(probably resulting in the oxidation of
myocardial proteins, as shown in Figure 1)
and NO leads to the formation of perox-
ynitrite, which reacts with protein tyro-
sine residues to generate nitrotyrosine
(9). Earlier, it was found that myocardial
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Figure 3. Detection of poly(ADP-ribosyl)ation. Human ventricular tissue homogenates
(D, donor; F, failing) were loaded onto 5% to 20% gradient SDS-polyacrylamide gels (20 μg
of protein in each lane) and probed with a poly-ADP-ribose-specific antibody (1:10,000;
Calbiochem). According to the manufacturer’s data sheet, this antibody recognizes
poly-ADP-ribosylated proteins specifically and serum albumin nonspecifically (indicated).
The most prominent nitrotyrosine-specific band (indicated) was further evaluated for pur-
poses of densitometry. Mean values and SEM are shown in the bar graph (donor, n = 5;
failing, n = 8; P = 0.005).
proteins (such as alfa-actinin) could be
nitrated by peroxynitrite treatment, in
vitro, with a consequent decrease in the
contractile force (10). Via the same ap-
proach, failing and donor hearts were
tested for nitrated proteins: no difference
was found (Figure 2). It should be noted
that in vitro peroxynitrite treatment re-
sulted in a robust signal (Figure 2), indi-
cating that the experimental system was
sensitive to protein tyrosine nitration.
Additionally, no significant nitrotyrosine
staining was found in donor or failing
hearts (data not shown), confirming the
absence of nitrotyrosine-producing (ni-
trosative) stress.
Oxidative stress is associated with the
activation of PARP in many cells and tis-
sues (11). To determine the level of PARP
activation, donor and failing heart sam-
ples were screened for poly-ADP ribosy-
lated proteins (Figure 3). As assessed by
semiquantitative densitometry, the level
of poly-ADP ribosylated proteins was in-
creased 2.3-fold in the failing hearts com-
pared with the donor hearts (49.0 ± 16.2,
n = 8, in the donor hearts and 21.4 ± 8.8,
n = 5, in the failing hearts; P = 0.005). In-
vestigation of the subcellular pattern of
poly-ADP ribosylated proteins demon-
strated an obvious nuclear localization in
the failing hearts (Figure 4). Relative to the
donor hearts, the PAR-positive nuclei were
3.1-fold more abundant (20.8% ± 7.1% in
the donor hearts and 64.0% ± 2.2% in the
failing hearts). The nominal difference be-
tween the western immunoblot technique
(a 2.3-fold elevation in poly-ADP ribosy-
lated proteins) and the immunohisto-
chemical data (a 3.1-fold increase in PAR-
positive nuclei) may suggest a higher
sensitivity of the latter approach.
Activation of PARP-1 often results in
AIF-mediated apoptosis. To test the initia-
tion of the apoptotic program, the local-
ization of AIF was also tested (Figure 4);
no translocation (indicative of AIF activa-
tion) was found in donor or failing hearts.
An elevation in poly-ADP ribosylation
may be due either to a higher expression
of PARP-1 or to catalytic activation of the
enzyme (12). PARP-1 expression was
tested in the donor and in the failing
heart samples with a PARP-1–specific
antibody (Figure 5), and no significant
difference was found (in the donor
hearts 13.1 ± 6.7, n = 5, and 19.9 ± 3.1,
n = 7 in the failing hearts; P = 0.33).
Interestingly, a high level of degradation
of PARP-1 was detected in both the fail-
ing and the donor hearts. This is in ac-
cordance with the finding that PARP-1
activation is often followed by the poly-
ADP ribosylation of PARP-1 and by pro-
teolytic degradation and inactivation
(11). It is not clear what is the relevance
of the variability in expression (for exam-
ple, donor 1 and 2 compared with donor
3 and 4) or in degradation of PARP-1 (for
example, samples 3, 4, and 5) in the
donor samples (Figure 5). It is possible
that variability in the donor sample pool
or differences in the collection of the
samples may contribute to the diversity
in both the donor and the failing hearts.
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Figure 4. Immunohistochemical analysis of poly-ADP-ribosylation. Poly-ADP-ribosylated
proteins (A) or AIF (B) were detected on frozen sections from donor (a and c) and failing
(b and d) left ventricular tissue samples with antibodies against poly-ADP-ribose poly-
mers (1:100; Calbiochem) or against AIF (1:100; Chemicon), using the ABC method and
DAB as chromogen. Sections were counterstained with hematoxylin. Control sections
from donor and failing hearts were simultaneously stained with omission of the primary
antibody and no significant staining was observed (data not shown). Three samples
were evaluated from both donor and failing hearts and representative pictures are
shown. The indicated regions on the pictures recorded with low magnification (squares
in pictures a, b, c, and d) are also shown in higher magnification, labeled by capital let-
ters (A, B, C and D), respectively.
Caspases are well-known proteases ca-
pable of PARP cleavage and the promo-
tion of apoptosis (11,13). The activation of
one of the upstream caspases (caspase-9)
was analyzed in our samples. Procaspase-9
(not cleaved, inactive caspase-9) expres-
sion was approximately 3-fold lower in
the donor hearts than in the failing hearts
(3.7 ± 0.6, n = 8, in the donor hearts and
12.3 ± 2.2, n = 5, in the failing hearts; P =
0.009), as determined by densitometry of
caspase-9–specific bands using Western
immunoblot (Figure 6).
DISCUSSION
Experimental and clinical studies have
demonstrated the increased production
of reactive oxygen species (ROS) (super-
oxide, H2O2, and hydroxyl radical) in the
pathogenesis of acute and chronic heart
failure. Plasma malondialdehyde-like ac-
tivity, a marker of lipid peroxidation, is
increased in patients with ischemic and
nonischemic dilated cardiomyopathy; it
correlates with the severity of the symp-
toms, and exhibits an inverse relation-
ship with the ejection fraction and the
exercise capacity (14). The pericardial
concentration of 8-iso-PGF2 (a marker
for ROS production) correlates closely
with the end-systolic and end-diastolic
diameters of the left ventricle and with
the functional severity of heart failure
(15). Furthermore, there is a significant
positive correlation between myocardial
ROS production and left ventricular con-
tractile dysfunction in experimental
models (16).
Myocardial ROS generation is trig-
gered by repetitive episodes of ischemia
and reperfusion, by inflammatory cyto-
kines, by catecholamine auto-oxidation,
and by prostaglandin biosynthesis (1).
Impaired antioxidant defense mecha-
nisms (superoxide dismutase, catalase,
and glutathione peroxidase) or reduced
concentrations of endogenous antioxi-
dants (vitamin E, ascorbic acid, and
cysteine) can contribute to an increased
ROS production within the myocar-
dium (17). Sources of ROS in the failing
myocardium include xanthine oxido-
reductases, cyclooxygenases, the mito-
chondrial electron transport chain
(complex I), activated neutrophils,
NOS, and the auto-oxidation of certain
tissue metabolites and NAD(P)H oxi-
doreductases (1-6,17). The current re-
sults are consistent with these findings
and demonstrate the presence of signifi-
cant oxidative stress in failing human
heart samples, whereas the control
donor hearts displayed low levels of
oxidative stress. The latter finding is
consistent with the view that the collec-
tion of the hearts and the storage and
the processing of the samples during
our procedures do not trigger a signifi-
cant degree of oxidant generation.
The cardiomyocytes, the endocardial
endothelium, the coronary endothelium,
and the cardiac nerves are sites of NO
production by Ca2+-dependent NOS. NO
serves a number of important physiolog-
ical roles in the regulation of cardiac
function, including coronary vasodila-
tion, inhibition of platelet and neutrophil
adhesion and activation, modulation of
the cardiac contractile function, and inhi-
bition of cardiac oxygen consumption
(18). Although NO is essential in cardiac
physiology (18), at higher levels, or in
the presence of reactive oxygen species,
NO can also exert cytotoxic effects. Many
of the toxic actions of NO are not due to
NO directly, but are mediated via the
production of the highly reactive oxidant
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Figure 5. Detection of poly(ADP-ribose) polymerase (PARP-1) expression. Human ventricu-
lar tissue samples (F, failing; D, donor) were loaded (15 μg of protein in each lane) onto
10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The mem-
branes were probed with a PARP-1–specific antibody (1:10,000; Calbiochem) and also
stained with Ponceau. In the densitometric analysis, the optical density of the band rep-
resenting full-length PARP-1 (indicated) was corrected with the loading, and the mean
values ± SEM are shown in the bar graph (donor, n = 5; failing, n = 7; P = 0.33).
peroxynitrite, the reaction product of NO
and superoxide (9,19).
Animal models of heart failure have
furnished ample evidence of both the
overproduction of NO and the genera-
tion of peroxynitrite (at least as evi-
denced by its footprint, nitrotyrosine).
NO is overproduced in the failing my-
ocardium as a consequence of the in-
creased expression and activity of iNOS
(20). There is a correlation between the
chronic overexpression of iNOS and per-
oxynitrite generation and cardiac en-
largement, conduction defects, sudden
cardiac death, and less commonly, heart
failure in mice (21). Myocardial iNOS is
induced in rats with volume-overload
heart failure, and increased iNOS activity
leads to a loss of myocardial contractility
and β-adrenergic hyporesponsiveness
(22). Neuronal NOS-derived NO produc-
tion has also been demonstrated in the
failing human heart (23). Although per-
oxynitrite generation has been reported
in various forms of acute and chronic
heart failure in many animal models (24-
26) and in some human studies (27,28),
we failed to detect differences in tyrosine
nitration in the failing and donor hearts,
even though the evidence of massive ty-
rosine nitration in the positive controls
demonstrates that the assay used was
adequate (Figure 2, data not shown for
the immunohistochemistry). It is possi-
ble, however, that low, subthreshold lev-
els of nitrotyrosine are present in our
samples, and it is also conceivable that
peroxynitrite formation and tyrosine ni-
tration follow a particular time course
and our samples were taken from pa-
tients where tyrosine nitration was no
longer present.
Three particular pathways initiated
by ROS and reactive nitrogen species in
the failing heart are related to the acti-
vation of PARP: activation of caspases,
activation of MMPs, and DNA strand
breaks (12). As far as PARP activation is
concerned, it has been demonstrated in
ischemia-, banding-, diabetes-, and
cardiotoxic drug–induced heart failure
in murine studies (4,7,29-31). There is
multiple evidence of the activation of
caspases, and this issue has been
widely investigated and debated in
light of the relevance or nonrelevance
of apoptosis in the context of chronic
heart failure (32-34). The activation of
MMPs also been revealed in heart fail-
ure (35,36). It is important that both
caspases and MMPs have the ability to
induce the cleavage of PARP-1 in heart
failure (32-36).
The present study has yielded evi-
dence of PARP activation in myocardial
samples from patients with heart failure.
Thus, the current study adds a further
example of a human disease in which
PARP activation has been demonstrated.
Previous work has demonstrated PARP
activation, among others, in human dia-
betic microvessels (37). The current find-
ings are also consistent with a recent re-
port by Pillai, DiNapoli and colleagues of
increased poly(ADP-ribosyl)ation in
human failing hearts (31,32). However, in
contrast with Pillai, DiNapoli and col-
leagues (31,32), we were unable to detect
the upregulation of PARP-1 protein in
the heart failure samples (Figure 4),
which suggests that the increased
poly(ADP-ribosyl)ation in our samples
was most probably due to activation of
the catalytic function of PARP. This can
occur via two principal mechanisms:
breaks in the DNA strands or increased
intracellular calcium concentration
(12,38). Both of these mechanisms have
been demonstrated in failing hearts, and
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Figure 6. Detection of caspase-9 expression. Human ventricular tissue samples (F, failing;
D, donor) were loaded (15 μg of protein in each lane) onto 10% SDS-polyacrylamide
gels and transferred to nitrocellulose membranes. The membranes were probed with a
caspase-9–specific antibody (1:1000; Cell Signaling) and also stained with Ponceau. In
the quantification, the optical density of the band denoting the full-length caspase-9
(procaspase-9, indicated) was corrected with the loading, and the mean values ± SEM
are shown on the bar graph (donor, n = 5; failing, n = 8; P = 0.009).
in theory, both mechanisms could con-
tribute to PARP activation.
The activation of caspases may poten-
tially be triggered by two different
mechanisms. In one of these, initiator
caspases such as caspase-8 or -9 are acti-
vated in a multimeric complex (for ex-
ample, caspase-8 in the death-inducing
signaling complex and caspase-9 at the
apoptosome). Alternatively, caspases are
activated by catalytic processing of the
zymogens at specific cleavage sites (13).
Because of the central role of caspase-9
in the activation of PARP-1–degrading
enzyme pathways (11), an effort was
made to detect caspase-9 in our system;
our data demonstrated that it is over-
expressed (a higher expression of pro-
caspase) and activated (a higher level of
the proteolytically activated form). Acti-
vated caspases may trigger the cleavage
of PARP (11), and may also act upon a
variety of intracellular targets to pro-
mote apoptosis (13). The relationship be-
tween PARP activation and PARP cleav-
age, apoptosis vs. necrosis, is complex,
but accumulating evidence suggests that
PARP activation contributes to cell
necrosis, while PARP cleavage (leading
to a decreased PARP-1 activity) may
serve as a protective mechanism (to pre-
vent necrosis by cellular energy exhaus-
tion) and thereby permit apoptosis (12).
Interestingly, it was found that cardio-
plegic arrest induces apoptosis signaling
pathways in myocardial endothelial cells
and cardiac myocytes (39). In our case,
however, we did not find significant
translocation of AIF, suggesting that
these apoptotic pathways were not acti-
vated in the donor or in failing hearts
studied here.
Caspase-9 expression and the level of
activated caspase-9 were higher in failing
hearts than in donor hearts. The rele-
vance of this finding is not clear. On the
one hand, caspases can initiate the deg-
radation of PARP-1, which degradation
was indeed observed in the case of fail-
ing hearts. On the other hand, caspase
activation can promote apoptosis, which
is in contrast with the apparent lack of
AIF translocation in both donor and fail-
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ing hearts. It is therefore possible that
caspase-9 overexpression and higher ac-
tivation is a bystander effect of PARP-1
activation/degradation or apoptosis.
It is clear that further experiments
(using biopsies obtained at different
stages of heart failure) are required to
clarify the relationship between apoptosis
and PARP-1 activation. For example, such
endocardial biopsies were taken and
evaluated for apoptotic markers in the
case of dilatative cardiomyopathy (40-44).
Interestingly, controversial results were
obtained, suggesting that the therapy of
the patients or methodical difficulties (ob-
taining endocardial biopsies from the
same locations) affect the results of the
apoptotic tests. It should be also taken
into account that a rather diverse set of
human heart samples were analyzed.
Therefore the etiology of the heart failure
could have contributed to some of the
differences seen (coronary heart disease,
which is ischemic and would be expected
to lead to enhanced oxidative stress, vs. a
dilated cardiomyopathy, which could be
from alcohol or a virus).
Our data suggest that PARP-1 activa-
tion did not result in the initiation of
apoptosis in failing human hearts, ac-
cording to the absence of AIF transloca-
tion. It is therefore possible that PARP-1
is activated by a limited number of DNA
breaks as an important element of the
DNA repair system. Additionally, it
should be considered that our samples
were from end-stage failing hearts,
which may have successfully adapted to
the higher level of oxidative stress and to
the consequent PARP-1 activation. Alto-
gether, it cannot be ruled out that acute
PARP-1 activation results in apoptosis in
the case of other pathologies (for exam-
ple, in case of ischemia-reperfusion).
In animal studies, potent antioxidant
compounds and potent PARP inhibitors
exhibit significant efficacy in preventing
myocardial dysfunction, reducing hyper-
trophy, and improving myocardial effi-
cacy (38), suggesting that oxidative stress
and PARP activation are related. It is cer-
tainly important to perform clinical stud-
ies to determine the potential causative
role of the oxidative/nitrosative stress/
PARP pathway in the pathogenesis of
human heart failure. Overall, the current
study has clearly provided evidence of
oxidative stress and PARP activation in
human failing heart samples, confirming
earlier animal results in human tissue
samples and supporting the design of fu-
ture clinical trials.
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